business

Truist cuts Regeneron stock price target on LAG-3 trial miss

Investing.com · May 18, 2026, 10:12 AM · Also reported by 4 other sources

Read full story on Investing.com → More top stories

Also covered by

Yahoo Finance Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda Yahoo Finance Citi Raises Nextpower (NXT) Price Target by $31 Yahoo Finance Sunrun (RUN) Price Target Lowered Despite Exceeding Estimates in Q1 Yahoo Finance Ormat Technologies (ORA) Price Target Raised Following Strong Q1

Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Truist cuts Regeneron stock price target on LAG-3 trial miss

Also covered by

More in business